About 32 results found for searched term "STAT3-IN-7" (0.109 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49684 | STAT3-IN-17 | STAT |
| STAT3-IN-17 is a moderate STAT3 inhibitor (IC50=0.7 μM; HEK-Blue IL-6), with antiproliferative activity in HeLa cells. | ||
| M49686 | STAT3-IN-7 | STAT |
| STAT3-IN-7, an aryl sulfonamido azetidine compound, is an orally active STAT3 inhibitor. | ||
| M1782 | NSC 74859 (S3I-201) | STAT |
| S3I-201 | ||
| NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC50 of 86 μM. NSC 74859 (S3I-201) is effective in hepatocellular cancers with disrupted TGF-beta signaling.*The compound is unstable in solutions, freshly prepared is recommended | ||
| M9217 | Givinostat | HDAC |
| ITF2357 | ||
| Givinostat (ITF-2357) is an HDAC inhibitor with IC50s of 198 and 157 nM for HDAC1 and HDAC3, respectively. | ||
| M2111 | Fimepinostat | HDAC |
| CUDC-907 | ||
| Fimepinostat (CUDC-907) is a potent, orally-available small molecule dual PI3K and HDAC inhibitor, with IC50 values of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10, respectively. | ||
| M3032 | Stattic | STAT |
| Stattic is the first nonpeptidic STAT3 inhibitor, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1. Stattic inhibits STAT3 phosphorylation (at Y705 and S727). | ||
| M4288 | Atractylenolide I | TLR |
| Atractylenolide I is a sesquiterpene obtained from the roots of Atractylenolide. Atractylenolide I has neuroprotective, anti-allergic, anti-inflammatory and anticancer activities. Atractylenolide I is an antagonist of TLR4 and can also reduce the phosphorylation of JAK2 and STAT3 in A375 cells. | ||
| M4647 | Phorbol 12-myristate 13-acetate | PKC |
| PMA, TPA, 12-O-tetradecanoyl-phorbol-13-acetate; 12,13-tetradecanoyl phorbol acetate | ||
| Phorbol 12-myristate 13-acetate (PMA) is a dual SphK and protein kinase C (PKC) activator, increases the intracellular Ca2+ concentration ([Ca2+]i) in a dose-dependent manner, with an EC50 of 11.7 nM. | ||
| M5233 | Osilodrostat | Mineralocorticoid Receptor |
| LCI699 | ||
| Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. | ||
| M5807 | Napabucasin (BBI608) | STAT |
| BBI608; BB608 | ||
| Napabucasin (BBI608) is a first-in-class, orally active inhibitor of Stat3 that blocks stem cell activity in cancer cells by targeting the signal transducer and activator of transcription 3 pathway. Napabucasin inhibits cell proliferation of U87MG tumor xenografts in mice. | ||
| M7500 | YK 3-237 | Sirtuin |
| YK 3-237 is a boronic acid chalcone analog of combretastatin a4 (CA-4) and a SIRT1 activator that targets mutant p53. YK 3-237 can reduce the acetylation of mutant p53 protein by activating the SIRT1 enzyme, resulting in a significant decrease in the level of mutant p53 protein. YK-3-237 showed antiproliferative activity against tumor cells containing mutant p53 protein. | ||
| M7647 | Bryostatin 1 | PKC |
| Bryostatin 1 is a natural macrolide isolated from the moss bug Bugula neritina and a potent PKC modulator of central nervous system (CNS) permeability.Bryostatin 1 binds to the isolated Munc13-1 C1 domain and the full-length Munc13-1 protein with a Ki value of 8.07 and 0.45 nM, respectively, and has anticancer, anti-inflammatory and neuroprotective activities. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with Ki values of 8.07 nM and 0.45 nM, respectively, and exhibits anticancer, anti-inflammatory, and neuroprotective activities. | ||
| M8874 | C188-9 | STAT |
| TTI-101 | ||
| C188-9 is a small-molecule STAT3 inhibitor, can block Th2 and Th17 cell expansion and cytokine production to prevent house dust mite (HDM)-induced airway inflammation and remodeling. | ||
| M13678 | Resminostat hydrochloride | HDAC |
| RAS2410 hydrochloride; 4SC-201 hydrochloride | ||
| Resminostat hydrochloride is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC50 values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC50 of 877 nM. | ||
| M14148 | STAT3-IN-1 | STAT |
| STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis. | ||
| M14473 | Prinomastat | MMP |
| AG3340; KB-R9896 | ||
| Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. | ||
| M18434 | Ginkgolic acid 17:1 | PTEN |
| Ginkgolic acid 17:1, a natural product isolated from Ginkgo biloba, inhibits constitutive and inducible STAT3 activation by inducing PTEN and SHP-1 tyrosine phosphatases. In addition, Ginkgolic acid C17:1 has anticancer activity. | ||
| M20389 | Quisinostat (JNJ-26481585) 2HCl | HDAC |
| Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11 greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2. | ||
| M21677 | Recombinant Human Follistatin 288 (HEK293, C-6His) | Cytokines and Growth Factors |
| FST; follistatin isoform FST317 | ||
| Follistatin 288 is a secreted glycoprotein that was first identified as a follicle-stimulating hormone inhibiting substance in ovarian follicular fluid . Human follistatin 288 cDNA encodes a 317 amino acid (aa) protein with a 29 aa signal sequence, and a 288 aa mature region. Recombinant Human Follistatin/FST is produced by Mammalian expression system and the target gene encoding Gly30-Asn317 is expressed with a 6His tag at the C-terminus. | ||
| M27692 | STAT3-IN-5 | STAT |
| STAT3-IN-5 is a potent STAT3 inhibitor. STAT3-IN-5 inhibits STAT3-Y705 phosphorylation with an EC50 value of 170 nM. STAT3-IN-5 inhibits cytokine induced JAK activation. STAT3-IN-5 induces apoptosis. STAT3-IN-5 can be used in research of cancer. | ||
| M28169 | Osilodrostat phosphate | Mineralocorticoid Receptor |
| LCI699 phosphate | ||
| Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. | ||
| M28184 | Debio 0617B | STAT |
| Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors. | ||
| M29087 | Givinostat hydrochloride | HDAC |
| ITF-2357 hydrochloride | ||
| Givinostat (ITF-2357) hydrochloride is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. | ||
| M29315 | Feniralstat | Serine/Threonine Protease |
| Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC50 of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC50>40 μM). | ||
| M30026 | UC-112 | IAP |
| UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor. UC-112 potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM). | ||
| M30649 | C188 | STAT |
| CPD188 | ||
| C188 is a STAT3 inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket. C188, in particular, was highly active in inducing apoptosis of the breast cancer cell line MB-MDA-468 in vitro (EC50= 0.7 μM). | ||
| M31205 | G5-7 | JAK |
| G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study. | ||
| M40707 | Icotrokinra | IL Receptor/Related |
| JNJ-2113; JNJ-77242113; PN-235 | ||
| Icotrokinra (JNJ-77242113, JNJ-2113) is a novel, orally active IL-23R peptide antagonist for studies related to plaque psoriasis. Icotrokinra exhibits high affinity with human IL-23 receptor hIL-23R with a Kd of 7.1 pM. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in PMBCs (IC50=5.6 pM), and inhibits L-23-induced generation of IFNγ and IL-17A in picomolar levels. | ||
| M49655 | HP590 | STAT |
| HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). | ||
| M49660 | STX-0119 | STAT |
| STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM. | ||
| M49663 | Antitumor agent-73 | STAT |
| Antitumor agent-73 is a Diosgenin derivative, which inhibits STAT3 signaling and activates Pdia3/ERp57 exogenously. | ||
| M49679 | STAT3-IN-11 | STAT |
| STAT3-IN-11 is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
